Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1981-10-29
|
pubmed:abstractText |
Twenty-nine patients with metastatic sarcoma were treated with a combination of methyl CCNU and actinomycin D. Patients with adequate bone marrow reserve received methyl CCNU 100 mg/m2 orally on day 1 and actinomycin D 0.3 mg/m2/day intravenously for five days. Both drugs were repeated every four weeks. Patients with inadequate bone marrow reserve received methyl CCNU 75 mg/m2 and actinomycin D 0.2 mg/m2/day for five days. All patients had received prior chemotherapy and had progressive disease at the start of the study. There was one complete response in a patient with peritoneal mesothelioma which lasted 18 months and the patient is still alive at 38+ months. Ten patients had stable disease including three patients who had responses between 25% to 50%. No responses were seen in 18 patients. The median time to progression for patients with stable disease was five months and for those with progressive disease was two months (P = 0.001). The median survival for patients with stable disease was 20 months compared with three months for patients with progressive disease (P = 0.001). The combination was generally very well tolerated and myelosuppression was insignificant. However, with the dosages and schedule used in this study, the combination of methyl CCNU and actinomycin D does not appear to have significant activity in advanced soft tissue sarcomas. Further studies with this combination are indicated in patients with mesothelioma.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0008-543X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2807-9
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7260872-Adult,
pubmed-meshheading:7260872-Aged,
pubmed-meshheading:7260872-Bone Neoplasms,
pubmed-meshheading:7260872-Dactinomycin,
pubmed-meshheading:7260872-Drug Administration Schedule,
pubmed-meshheading:7260872-Drug Evaluation,
pubmed-meshheading:7260872-Drug Therapy, Combination,
pubmed-meshheading:7260872-Female,
pubmed-meshheading:7260872-Humans,
pubmed-meshheading:7260872-Male,
pubmed-meshheading:7260872-Middle Aged,
pubmed-meshheading:7260872-Nitrosourea Compounds,
pubmed-meshheading:7260872-Sarcoma,
pubmed-meshheading:7260872-Semustine,
pubmed-meshheading:7260872-Soft Tissue Neoplasms
|
pubmed:year |
1981
|
pubmed:articleTitle |
A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|